SKYEPHARMA PLC Form SC 13G/A February 13, 2009

> OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response...10.4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 2)*

SKYEPHARMA PLC (Name of Issuer) Common Stock (Title of Class of Securities) G1145K144 (CUSIP Number) December 31, 2008 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

þ Rule 13d-1(b)

o Rule 13d-1(c)

o Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

NAMES OF REPORTING PERSONS

1 UBS AG (for the benefit and on behalf of UBS Investment Bank, Wealth Management USA, and Global Wealth Management and Business Banking business groups of UBS AG (See Item 7))

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

2

(a) o

(b) o

SEC USE ONLY

3

4

Switzerland

SOLE VOTING POWER 5 NUMBER OF Less than 5% **SHARES** SHARED VOTING POWER BENEFICIALLY 6 OWNED BY 0 EACH SOLE DISPOSITIVE POWER 7 REPORTING PERSON Less than 5% WITH: SHARED DISPOSITIVE POWER 8 0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9

Less than 5%

Edgar Filing: SKYEPHARMA PLC - Form SC 13G/A

10CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE
INSTRUCTIONS)0011PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)11Less than 5%TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

12

BK

Item 1(a) Name of Issuer SKYEPHARMA PLC Item 1(b) Address of Issuer s Principal Executive Offices: 105 Piccadilly London, W1J 7NJ United Kingdom Item 2(a) Name of Person Filing: UBS AG Item 2(b) Address of Principal Business Office: UBS AG s principal business office is: Bahnhofstrasse 45 PO Box CH-8021 Zurich, Switzerland Item 2(c) Citizenship: Switzerland Item 2(d) Title of Class of Securities Common Stock Item 2(e) CUSIP Number: G1145K144

Item 3. Type of Person Filing:

UBS AG is classified as a Bank as defined in section 3(a)(6) of the Act pursuant to no-action relief granted by the staff of the Securities and Exchange Commission.

Item 4 (a)-(c)(iv). Ownership:

Items 5-11 of the cover pages are incorporated by reference.

Item 5. Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following b.

Item 6. Ownership of More than Five Percent on Behalf of Another Person:

Not applicable

UBS Portfolio LLC

Item 7. Identification and Classification of the Subsidiary That Acquired the Security Being Reported on By the Parent Holding Company:

This statement on Schedule 13G is being filed by UBS AG on behalf of itself and the subsidiaries listed below. The securities being reported on by UBS AG were acquired directly by UBS AG directly and certain of such subsidiaries. UBS AG London Branch

UBS AG Frankfurt UBS Ltd UBS Warburg Private Clients Ltd UBS AG Tokyo branch UBS AG (Switzerland) UBS Warburg Securities (Pty) Ltd (South Africa) UBS International Ltd UBS Warburg Securities Ltd Banco UBS Warburg S.A UBS Warburg Corretora de Cambio e Valores Mobiliarios S.A.

UBS Warburg Trading S.A.

UBS Bunting Warburg Inc

UBS Capital Americas Investments III, Ltd.

UBS Capital II LLC **UBS** Capital LLC **UBS AG Brazil UBS** Limited UBS Capital Americas Investments II Ltd SBC Equity Partners AG UBS Capital Asia Pacific Ltd **UBS** Capital Holdings LLC **UBS** Capital Jersey Ltd **UBS** Capital BV UBS (USA) Inc UBS Warburg AG (Frankfurt) UBS Securities Australia Ltd UBS Securities (Japan) Ltd **UBS Securities LLC UBS** Securities New Zealand Limited **UBS New Zealand Limited** UBS AG Australia Branch **UBS** Capital Markets LP UBS Capital Latin America LDC **UBS Securities France SA** UBS AG Canada Branch UBS Cayman Ltd. PaineWebber Capital Inc Paine Webber International Inc **UBS Fiduciary Trust Company** UBS Financial Services Incorporated of Puerto Rico **UBS** Americas Inc **UBS** Financial Services Inc. Inversiones Ibersuizas, S.A. UBS (Bahamas) LTD UBS (Cayman Islands) LTD UBS (France) LTD UBS (Italia) LTD UBS (Luxemberg) LTD UBS (Luxemberg) SA Austria Branch UBS (Monaco) S.A. **UBS AG Brazil** UBS AG New York (101 Park Avenue) **UBS AG Hong Kong** UBS AG Jersey Branch **UBS AG Singapore UBS** Assessores LTD UBS Bank (Canada) **UBS Belgium SA/NV** UBS Deutschland AG UBS Espana S.A. **UBS** International Inc **UBS Swiss Advisors AG**

Edgar Filing: SKYEPHARMA PLC - Form SC 13G/A

UBS Wealth Management AG UBS Wealth Management (UK) Ltd Banco UBS Pactual SA Item 8. Identification and Classification of Members of the Group Not Applicable Item 9 Notice of Dissolution of Group: Not Applicable Item 10. Certification:

By signing below, the undersigned certify that, to the best of their knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Edgar Filing: SKYEPHARMA PLC - Form SC 13G/A

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

- By: /s/ Anthony Defilippis Anthony Defilippis Executive Director
- By: /s/ Gordon Kiesling Gordon Kiesling Executive Director

Date: February 13, 2009